C4 Therapeutics Inc (NASDAQ:CCCC) — Market Cap & Net Worth
Market Cap & Net Worth: C4 Therapeutics Inc (CCCC)
C4 Therapeutics Inc (NASDAQ:CCCC) has a market capitalization of $404.68 Million ($404.68 Million) as of June 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13517 globally and #3212 in its home market, demonstrating a 6.96% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying C4 Therapeutics Inc's stock price $3.84 by its total outstanding shares 110567222 (110.57 Million). Review C4 Therapeutics Inc debt and liabilities to assess the company's total debt and financial obligations.
C4 Therapeutics Inc Market Cap History: 2020 to 2026
C4 Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows change from $3.66 Billion to $424.58 Million (-28.23% CAGR).
Index Memberships
C4 Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.43 Trillion | 0.02% | #356 of 976 |
|
NASDAQ Composite
IXIC
|
$41.27 Trillion | 0.00% | #1304 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.02% | #194 of 263 |
Weight: C4 Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
C4 Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how C4 Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.87x
C4 Therapeutics Inc's market cap is 5.87 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.66 Billion | $33.20 Million | -$66.33 Million | 110.35x | N/A |
| 2021 | $3.56 Billion | $45.78 Million | -$83.89 Million | 77.76x | N/A |
| 2022 | $652.35 Million | $31.10 Million | -$128.18 Million | 20.98x | N/A |
| 2023 | $624.70 Million | $20.76 Million | -$132.49 Million | 30.10x | N/A |
| 2024 | $398.04 Million | $35.58 Million | -$105.32 Million | 11.19x | N/A |
| 2025 | $211.18 Million | $35.95 Million | -$104.99 Million | 5.87x | N/A |
Competitor Companies of CCCC by Market Capitalization
Companies near C4 Therapeutics Inc in the global market cap rankings as of June 17, 2026.
Key companies related to C4 Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #442 globally with a market cap of $63.33 Billion USD.
- UCB SA (BR:UCB): Ranked #550 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #574 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $453.17 |
| #442 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.33 Billion | $614.73 |
| #550 | UCB SA | BR:UCB | $49.68 Billion | €250.00 |
| #574 | Argen-X | BR:ARGX | $47.14 Billion | €755.80 |
C4 Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, C4 Therapeutics Inc's market cap moved from $3.66 Billion to $ 424.58 Million, with a yearly change of -28.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $424.58 Million | +101.05% |
| 2025 | $211.18 Million | -46.94% |
| 2024 | $398.04 Million | -36.28% |
| 2023 | $624.70 Million | -4.24% |
| 2022 | $652.35 Million | -81.68% |
| 2021 | $3.56 Billion | -2.81% |
| 2020 | $3.66 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of C4 Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $404.68 Million USD |
| MoneyControl | $404.68 Million USD |
| MarketWatch | $404.68 Million USD |
| marketcap.company | $404.68 Million USD |
| Reuters | $404.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About C4 Therapeutics Inc
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology p… Read more